Rapid Micro Biosystems’ $158.4 Million IPO

Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced the pricing of its initial public offering of 7,920,000 shares of its Class A common stock at a price to the public of $20.00 per share. All of the shares of Class A common stock are being offered by Rapid Micro. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Rapid Micro, are expected to be $158.4 million, excluding any exercise of the underwriters’ option to purchase additional shares. Rapid Micro’s Class A common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “RPID” on July 15, 2021. The offering is expected to close on July 19, 2021, subject to satisfaction of customary closing conditions. In addition, Rapid Micro has granted the underwriters a 30-day option to purchase up to an additional 1,188,000 shares of Rapid Micro’s Class A common stock at the initial public offering price less the underwriting discounts and commissions.

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers of the offering.

Headquartered in Lowell, MA, Rapid Micro Biosystems is a life sciences technology company providing automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products. The company’s Growth Direct platform provides the only fully automated, high-throughput and secure MQC solution that detects contamination more quickly, delivering compelling economic benefits while preventing quality control errors. For more information, please visit.

The Goodwin team was led by Mitchell Bloom (Picture) and Edwin O’Connor and included Humza Bokhari, Amanda Rae Schwarzenbart, Larissa Pinho, Lanru Qiao, Isabel Tule and summer associate Tianli Song with additional assistance from Duncan Greenhalgh, Martin Gomez, Gozde Guckaya, Jackie Klosek, Alexander Varond, Elizabeth Mulkey, Roger Cohen, Heath Roosevelt Ingram, Andrew Hess, Jacob Osborn, Justin Pierce, Daniel Karelitz, Peter LaVigne and Brad Weber.

Latham & Watkins LLP represented Rapid Micro Biosystems, Inc. in the offering with a Boston-based deal team led by partners Wesley Holmes and Stephen Ranere, with associates Jennifer Yoon, Tyler Mills, and Dante Spurlock.

Involved fees earner: Mitchell Bloom – Goodwin Procter; Humza Bokhari – Goodwin Procter; Roger Cohen – Goodwin Procter; Martin Gomez – Goodwin Procter; Duncan Greenhalgh – Goodwin Procter; Gozde Guckaya – Goodwin Procter; Andrew Hess – Goodwin Procter; Heath Ingram – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Jacqueline Klosek – Goodwin Procter; Peter LaVigne – Goodwin Procter; Elizabeth Mulkey – Goodwin Procter; Jacob Osborn – Goodwin Procter; Edwin O’Connor – Goodwin Procter; Justin Pierce – Goodwin Procter; Larissa Pinho – Goodwin Procter; Lanru Qiao – Goodwin Procter; Amanda Schwarzenbart – Goodwin Procter; Alexander Varond – Goodwin Procter; Bradley Weber – Goodwin Procter; Wesley Holmes – Latham & Watkins; Tyler Mills – Latham & Watkins; Stephen Ranere – Latham & Watkins; Dante Spurlock – Latham & Watkins; Jennifer Yoon – Latham & Watkins;

Law Firms: Goodwin Procter; Latham & Watkins;

Clients: Cowen and Company; J.P. Morgan Securities LLC; Morgan Stanley; Rapid Micro Biosystems; Stifel, Nicolaus & Company, Incorporated;

Author: Martina Bellini